Sharechat Logo

RAKON FY23 Earnings Guidance

Thursday 11th August 2022

Text too small?

Rakon (NZX: RAK ), an international leader in frequency control and timing solutions today announces it expects Underlying EBITDA1 for the year to 31 March 2023, to range between $36 million and $44 million. Even at the bottom of this range, the result would represent the second-best ever reported by the company.

The guidance is consistent with market expectations and comes ahead of the company’s Annual Meeting of Shareholders in Auckland today. It compares to the record $54.4 million Underlying EBITDA achieved in the 2022 financial year, a result lifted by the short-term opportunities created by a global chip shortage that followed a fire at one of the world’s largest chip manufacturers.

Rakon Chief Executive Dr Sinan Altug said: “The current financial year is an inflection point for the company. Core business is growing, and we are accelerating investment for the future where we see significant opportunities. These investments, the transition to the new Bengaluru, India facility and inflation pressures will moderate Underlying EBITDA in the current year.”

Dr Altug said the final outcome for the year is subject to a number of uncertainties including the global economic outlook and its impact on global demand, the ongoing raw materials and supply chain challenges and the execution of the transition to the new facility in India.

Rakon will provide further detail at its annual meeting today.

RAKON FY23 EARNINGS GUIDANCE



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK
TEM - Appointment to the Board of Directors
December 19th Morning Report
RAD - Radius Care Announces On-market Share Buyback Programme
MCY - New wind farm propels MCY renewables commitment to $1b